V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough

Lexicon Pharmaceuticals Executive Compensation (FY25)

LXRX · Executive and director compensation, fiscal 2023 to 2025

The Lexicon Pharmaceuticals brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 7, 2026Latest filing (8-K): April 30, 2026
15 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Lexicon Pharmaceuticals brief$1,500Get the executive brief
283 figures on this page: 272 cited to the filing that reported them, 11 calculated from figures it prints. See the citations
Chief executive, fiscal 2025
◇
Michael Exton
Latest say-on-pay support
=
April 30, 2026
Chief executive pay ratio
◇
To the median employee
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Michael Exton: $2,835,589 → $3,553,953 (25.3% higher)
Say-on-pay support: 96.5% → 97.7% (1.2 points higher)
CEO pay ratio: 10:1 → 13:1 (30.0% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Lexicon Pharmaceuticals' chief executive and what were they paid?
Michael Exton was paid $3,553,953 in total compensation as Chief Executive Officer and Director for fiscal 2025. Exton's total was 25.3% higher than the $2,835,589 reported for fiscal 2024.
What was Lexicon Pharmaceuticals' say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 97.7% of votes cast for or against in favor at the meeting held April 30, 2026.
Which companies are in Lexicon Pharmaceuticals' peer group?
Companies named in the disclosed peer group include Altimmune, Inc., AnaptysBio, Inc., Arbutus Biopharma Corporation, ARS Pharmaceuticals, Inc. and Avadel Pharmaceuticals plc, among others. The For compensation decisions made in February 2026 includes Gossamer Bio, Inc., Relay Therapeutics, Inc. and Tango Therapeutics, Inc.
What is Lexicon Pharmaceuticals' chief executive pay ratio?
The company reported a chief executive pay ratio of 13:1 for fiscal 2025.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Craig Granowitz
Senior Vice President and Chief Medical Officer
◇◇◇◇——◇◇
Brian Crum
Senior Vice President and General Counsel
◇◇◇◇——◇◇
Wendy McDermott
Senior Vice President, Human Resources
◇◇◇◇——◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Michael Exton
Chief Executive Officer and Director
◇◇—◇——◇◇
Craig Granowitz
Senior Vice President and Chief Medical Officer
◇◇◇◇——◇◇
Brian Crum
Senior Vice President and General Counsel
◇◇◇◇——◇◇
Wendy McDermott
Senior Vice President, Human Resources
◇◇◇◇——◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Michael Exton
Chief Executive Officer and Director
◇◇◇◇——◇◇
Craig Granowitz
Senior Vice President and Chief Medical Officer
◇◇◇◇——◇◇
Scott Coiante
Senior Vice President and Chief Financial Officer
◇◇◇◇——◇◇
Brian Crum
Senior Vice President and General Counsel
◇◇◇◇——◇◇
Wendy McDermott
Senior Vice President, Human Resources
◇◇◇◇——◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Brian T. CrumOPTION◇——◇—◇◇
Brian T. CrumRSU◇——◇——◇
Craig B. GranowitzOPTION◇——◇—◇◇
Craig B. GranowitzRSU◇——◇——◇
Michael S. ExtonRSU◇——◇——◇
Michael S. ExtonOPTION◇——◇—◇◇
Scott M. CoianteOPTION◇——◇—◇◇
Scott M. CoianteOPTION◇——◇—◇◇
Scott M. CoianteRSU◇——◇——◇
Wendy E. McDermottRSU◇——◇——◇
Wendy E. McDermottOPTION◇——◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Wendy McDermottOption◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
RSU◇◇——
Craig GranowitzOption◇—◇—
Option◇—◇—
Option◇—◇—
RSU◇◇——
Option◇—◇—
RSU◇◇——
RSU◇◇——
Scott CoianteOption◇—◇—
Option◇—◇—
RSU◇◇——
Brian CrumRSU◇◇——
Option◇—◇—
RSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Michael ExtonOption◇—◇—
Option◇—◇—
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Brian Crum
Senior Vice President and General Counsel · Change-in-control agreement
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Change-in-control base◇
Benefits continuation on change in control◇
Benefits continuation◇
Clawback◇
Craig Granowitz
Senior Vice President and Chief Medical Officer · Change-in-control agreement
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Clawback◇
Michael Exton
Chief Executive Officer and Director · Change-in-control agreement
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Change-in-control base◇
Benefits continuation on change in control◇
Benefits continuation◇
Clawback◇
Scott Coiante
Senior Vice President and Chief Financial Officer · Change-in-control agreement
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Change-in-control base◇
Benefits continuation on change in control◇
Benefits continuation◇
Clawback◇
Wendy McDermott
Senior Vice President, Human Resources · Change-in-control agreement
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Change-in-control base◇
Benefits continuation on change in control◇
Benefits continuation◇
Clawback◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Raymond Debbane
Board chair
◇◇◇———◇
Samuel L. Barker, Ph.D
◇◇◇———◇
Philippe J. Amouyal
◇◇◇———◇
Judith L. Swain, M.D
◇◇◇———◇
Diane E. Sullivan
◇◇◇———◇
Ivan H. Cheung
◇◇◇———◇
Christopher J. Sobecki
◇◇◇———◇
Michael S. Exton, Ph.D served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as RSUs and Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Altimmune, Inc. ALT
  • AnaptysBio, Inc. ANAB
  • Arbutus Biopharma Corporation ABUS
  • ARS Pharmaceuticals, Inc. SPRY
  • Avadel Pharmaceuticals plc AVDL
  • Cartesian Therapeutics, Inc. CRTS
  • CorMedix Inc. CRMD
  • Dianthus Therapeutics, Inc. DNTH
  • Entrada Therapeutics, Inc. TRDA
  • Eyepoint Pharmaceuticals, Inc. EYPT
  • Immunome, Inc. IMNM
  • Liquidia Corporation LQDA
  • Pliant Therapeutics, Inc. PLRX
  • Praxis Precision Medicines, Inc. PRAX
  • Prothena Corporation plc PRTA
  • Stoke Therapeutics, Inc. STOK
  • Syndax Pharmaceuticals, Inc. SNDX
  • Taysha Gene Therapies, Inc. TSHA
  • UroGen Pharma Ltd. URGN
For compensation decisions made in February 2026
  • Gossamer Bio, Inc. GOSS
  • Relay Therapeutics, Inc. RLAY
  • Tango Therapeutics, Inc. TNGX

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025April 30, 2026=◇◇◇
2024June 2, 2025=◇◇◇
2023May 10, 2024=◇◇◇
2022April 27, 2023=◇◇◇
2021May 20, 2022=◇◇◇
2020April 29, 2021=◇◇◇
2019April 23, 2020=◇◇◇
2018April 25, 2019=◇◇◇
2017April 26, 2018=◇◇◇
2016April 27, 2017=◇◇◇
2015April 28, 2016=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Lexicon Pharmaceuticals files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Lexicon Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Lexicon Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Lexicon Pharmaceuticals' disclosed peer group is defensible, who names Lexicon Pharmaceuticals back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
283 figures on this page: 272 cited to the filing that reported them, 11 calculated from figures it prints.
272 cited to the filing
11 calculated from the filing

Documents cited

  1. 0001062822-26-000065
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001062822-26-000056
    Director Compensation in 2025 · EXECUTIVE AND DIRECTOR COMPENSATION · Grants of Plan-Based Awards · Grants of Plan-Based Awards in 2025 · and 3 more sections
  3. 0001062822-25-000033
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001062822-25-000023
    Summary Compensation Table for 2024
  5. 0001062822-25-000013
    Employment Agreement
  6. 0001062822-24-000029
    Item 5.07 Submission of Matters to a Vote of Security Holders
  7. 0001062822-24-000014
    Summary Compensation Table for 2023
  8. 0001062822-23-000015
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0001062822-22-000024
  10. 0001062822-21-000029
  11. 0001062822-20-000025
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0001062822-19-000012
    Item 5.07 Submission of Matters to a Vote of Security Holders
  13. 0001062822-18-000017
    Item 5.07 Submission of Matters to a Vote of Security Holders
  14. 0001062822-17-000028
    Item 5.07 Submission of Matters to a Vote of Security Holders
  15. 0001062822-16-000060
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Lexicon Pharmaceuticals executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/LXRX (accessed 2026).
Short form: data: Velarion

The Lexicon Pharmaceuticals brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
15 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Lexicon Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers Lexicon Pharmaceuticals discloses

The companies named in LXRX's own disclosed peer group.

Altimmune, Inc.AnaptysBio, Inc.Arbutus Biopharma CorporationARS Pharmaceuticals, Inc.CorMedix Inc.Dianthus Therapeutics, Inc.Entrada Therapeutics, Inc.Eyepoint Pharmaceuticals, Inc.Immunome, Inc.Liquidia CorporationPliant Therapeutics, Inc.Praxis Precision Medicines, Inc.Prothena Corporation plcStoke Therapeutics, Inc.Syndax Pharmaceuticals, Inc.Taysha Gene Therapies, Inc.UroGen Pharma Ltd.Gossamer Bio, Inc.Relay Therapeutics, Inc.Tango Therapeutics, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy